产品编号 | bs-9790R-AP |
英文名称 | Rabbit Anti-AFAP/AP Conjugated antibody |
中文名称 | 碱性磷酸酶(AP)标记的微丝相关蛋白1抗体 |
别 名 | 110 kDa actin filament associated protein; 110 kDa actin filament-associated protein; Actin filament associated protein 1; Actin filament associated protein 110 kDa; Actin filament-associated protein 1; AFAP 1; AFAP 110; AFAP; AFAP-110; Afap1; AFAP1_HUMAN. |
规格价格 | 100ul/2980元 购买 大包装/询价 |
说 明 书 | 100ul |
研究领域 | 信号转导 细胞凋亡 细胞骨架 |
抗体来源 | Rabbit |
克隆类型 | Polyclonal |
交叉反应 | (predicted: Human, Mouse, Rat, Dog, Cow, Horse, Sheep, ) |
产品应用 | WB=1:50-200 IHC-P=1:50-200 IHC-F=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
分 子 量 | 81kDa |
性 状 | Lyophilized or Liquid |
浓 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human AFAP |
亚 型 | IgG |
纯化方法 | affinity purified by Protein A |
储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
产品介绍 |
background: Actin filament associated protein (AFAP-110) interacts directly with Actin filaments through its C-terminal Actin binding domain. AFAP-110 contains additional protein-binding domains as well, and serves as an adaptor protein. AFAP-110 links signaling molecules to Actin filaments, provides a platform for the preparation of larger signaling complexes, activates Src kinases in response to cellular signals and also directly affects Actin organization as an Actin filament cross-linking protein. Deletion of certain binding elements of AFAP-110 results in altered Actin phenotypes; for instance, deletion of the leucine zipper motif causes repositioning of Actin into rosettes. Because inhibition of certain Actin cytoskeletal conformations inhibits cell division and movement, these conformational changes to AFAP-110, and thus Actin organization in the cell, represent a possible therapeutic target for controlling tumorigenesis and metastasis. Function: Can cross-link actin filaments into both network and bundle structures (By similarity). May modulate changes in actin filament integrity and induce lamellipodia formation. May function as an adapter molecule that links other proteins, such as SRC and PKC to the actin cytoskeleton. Seems to play a role in the development and progression of prostate adenocarcinoma by regulating cell-matrix adhesions and migration in the cancer cells. Subunit: Monomer and homomultimer. Interacts via its C-terminus with F-actin; probably involving AFAP1 multimers (By similarity). Interacts with activated SRC SH3-SH2 domains. Interacts via its PH 1 domain with PRKCA, PRKCB and PRKCI (By similarity). Subcellular Location: Cytoplasm, cytoskeleton. Note=Localizes with stress fibers in quiescent cells, concentrated in cell motility structures such as lamellipodia, filopodia and membrane ruffles upon their induction. Tissue Specificity: Low expression in normal breast epithelial cell line MCF-10A and in tumorigenic breast cancer cell lines MCF-7, T-47D and ZR75-1. Highly expressed in the invasive breast cancer cell lines MDA-MB-231 and MDA-MB-435. Overexpressed in prostate carcinoma. Post-translational modifications: Phosphorylated on tyrosine residues by SRC. Similarity: Contains 2 PH domains. Database links: Entrez Gene: 60312 Human Entrez Gene: 70292 Mouse Omim: 608252 Human SwissProt: Q90738 Chicken SwissProt: Q8N556 Human SwissProt: Q80YS6 Mouse Unigene: 185 Chicken Unigene: 529369 Human Unigene: 125167 Mouse Unigene: 208751 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
1、抗体溶解方法 | |
2、抗体修复方式 | |
3、常用试剂的配制 | |
4、免疫组化操作步骤 | |
5、免疫组化问题解答 | |
6、Western Blotting 操作步骤 | |
7、Western Blotting 问题解答 | |
8、关于肽链的设计 | |
9、多肽的溶解与保存 | |
10、酶标抗体效价测定程序 | |